← All trials
NCT07174076
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 24, 2025
- Primary completion
- Jul 24, 2028
- Completion date
- Dec 31, 2028
- First posted
- Sep 15, 2025
- Last posted
- Sep 15, 2025
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Capital Medical UniversityLead sponsor
- Peking UniversityOfficial
- Huazhong University of Science and TechnologyCollaborator
- Anhui Medical UniversityCollaborator
- Peking UniversityCollaborator
- Capital Medical UniversitySponsor investigator
- Jiangxi Chest HospitalCollaborator
- Capital Medical UniversityCollaborator
- Hangzhou ZhongmeiCollaborator
- Guangzhou Chest Hospital.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.